Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment

Bone

Volumn 59, Issue , 2014, Pages 139-147

  Ma, Yanfei L ^a   Zeng, Qing Q ^a   Chiang, Alan Y ^a   Burr, David ^b   Li, Jiliang ^c   Dobnig, Harald ^d   Fahrleitner Pammer, Astrid ^d   Michalská, Dana ^e   Marin, Fernando ^a   Pavo, Imre ^a   Stepan, Jan J ^e  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alendronate; Bone biopsy; Bone formation; Cortical histomorphometry; Teriparatide

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; TETRACYCLINE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; ILIAC CREST; MIDDLE AGED; MINERAL APPOSITION RATE; MORPHOMETRICS; MUSCULOSKELETAL SYSTEM PARAMETERS; OSSIFICATION; OSTEOPOROSIS; PERIOSTEAL BONE FORMATION RATE; POROSITY; POSTMENOPAUSE;

ALENDRONATE; BONE BIOPSY; BONE FORMATION; CORTICAL HISTOMORPHOMETRY; TERIPARATIDE;

AGED; ALENDRONATE; CALCIFICATION, PHYSIOLOGIC; FEMALE; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

EID: 84889578208     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.011     Document Type: Article

References (60)

1. Burr D.B. Cortical bone: a target for fracture prevention?. Lancet 2010, 375:1672-1673.
2. Holzer G., von Skrbensky G., Holzer L.A., Pichl W. Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength. J Bone Miner Res 2009, 24:468-474.
3. Poole K.E., Treece G.M., Mayhew P.M., Vaculik J., Dungl P., Horak M., et al. Cortical thickness mapping to identify focal osteoporosis in patients with hip fracture. PLoS ONE 2012, 7:e38466.
4. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
5. Pfeilschifter J., Cooper C., Watts N.B., Flahive J., Saag K.G., Adachi J.D., et al. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporos Int 2012, 23:2179-2188.
6. Parfitt A.M. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. Osteoporosis 1996, 315-329. Academic Press, San Diego. R. Marcus, D. Feldman, J. Kelsey (Eds.).
7. Seeman E., Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
8. Murad M.H., Drake M.T., Mullan R.J., Mauck K.F., Stuart L.M., Lane M.A., et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012, 97:1871-1880.
9. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
10. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136:3632-3638.
11. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
12. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
13. Oxlund H., Ejersted C., Andreassen T.T., Torring O., Nilsson M.H. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int 1993, 53:394-399.
14. Wronski T.J., Yen C.F. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 1994, 15:51-58.
15. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
16. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., Watson P.H. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311-318.
17. Reeve J., Meunier P.J., Parsons J.A., Bernat M., Bijvoet O.L., Courpron P., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980, 280:1340-1344.
18. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
19. Ma Y.L., Zeng Q., Donley D.W., Ste-Marie L.G., Gallagher J.C., Dalsky G.P., et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:855-864.
20. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., Hodsman A.B. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22:495-502.
21. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006, 21:366-373.
22. Hirano T., Burr D.B., Cain R.L., Hock J.M. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 2000, 66:456-460.
23. Keaveny T.M., Hoffmann P.F., Singh M., Palermo L., Bilezikian J.P., Greenspan S.L., et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008, 23:1974-1982.
24. Graeff C., Timm W., Nickelsen T.N., Farrerons J., Marin F., Barker C., et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007, 22:1426-1433.
25. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
26. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 2004, 19:623-629.
27. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M., et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
28. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
29. Borggrefe J., Graeff C., Nickelsen T.N., Marin F., Gluer C.C. Quantitative computed tomographic assessment of the effects of 24months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010, 25:472-481.
30. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
31. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
32. Finkelstein J.S., Wyland J.J., Lee H., Neer R.M. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010, 95:1838-1845.
33. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., Hadji P., Farrerons J., Boonen S., et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008, 23:1591-1600.
34. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
35. Miller P.D., Delmas P.D., Lindsay R., Watts N.B., Luckey M., Adachi J., et al. Open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide I. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008, 93:3785-3793.
36. Stepan J.J., Burr D.B., Pavo I., Sipos A., Michalska D., Li J., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007, 41:378-385.
37. Stepan J.J., Burr D.B., Li J., Ma Y.L., Petto H., Sipos A., et al. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 2010, 21:2027-2036.
38. Ma Y.L., Marin F., Stepan J., Ish-Shalom S., Moricke R., Hawkins F., et al. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. Bone 2011, 48:972-978.
39. Foldes J., Shih M.S., Parfitt A.M. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 1990, 5:1063-1067.
40. Recker R.R., Kimmel D.B., Dempster D., Weinstein R.S., Wronski T.J., Burr D.B. Issues in modern bone histomorphometry. Bone 2011, 49:955-964.
41. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomeclature, symbols, and units for bone histomorphometry: a 2012 update of the Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:1-16.
42. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
43. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
44. Recker R.R., Marin F., Ish-Shalom S., Moricke R., Hawkins F., Kapetanos G., et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009, 24:1358-1368.
45. Iida-Klein A., Lu S.S., Cosman F., Lindsay R., Dempster D.W. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 2007, 40:391-398.
46. Krege J.H., Wan X. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone 2012, 50:161-164.
47. Tanizawa T., Itoh A., Uchiyama T., Zhang L., Yamamoto N. Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis. Bone 1999, 25:493-499.
48. Keshawarz N.M., Recker R.R. Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Relat Res 1984, 5:223-228.
49. Han Z.H., Palnitkar S., Rao D.S., Nelson D., Parfitt A.M. Effect of ethnicity and age or menopause on the structure and geometry of iliac bone. J Bone Miner Res 1996, 11:1967-1975.
50. Power J., Loveridge N., Lyon A., Rushton N., Parker M., Reeve J. Bone remodeling at the endocortical surface of the human femoral neck: a mechanism for regional cortical thinning in cases of hip fracture. J Bone Miner Res 2003, 18:1775-1780.
51. Hirano T., Burr D.B., Turner C.H., Sato M., Cain R.L., Hock J.M. Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 1999, 14:536-545.
52. Balena R., Shih M.S., Parfitt A.M. Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 1992, 7:1475-1482.
53. Bare S.J., Recker S., Recker R., Kimmel D. Influence of estrogen status and alendronate on periosteal bone formation in the ilium of adult women. J Bone Miner Res 2005, 20(S1):S56.
54. Hauge E., Mosekilde L., Melsen F. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 1999, 25:389-395.
55. Eriksen E.F., Melsen F., Sod E., Barton I., Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 31:620-625.
56. Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., García-Hernandez P.A., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
57. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
58. Ebeling P.R., Burr D.B. Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?. J Bone Miner Res 2008, 23:2-5.
59. Compston J.E. Zoledronic acid-does it have anabolic as well as antiresorptive effects?. IBMS BoneKEy 2008, 5:103-107.
60. Dempster D.W., Zhou H., Recker R.R., Brown J.P., Bolognese M.A., Recknor C.P., et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 2012, 97:2799-2808.